Company intelligence / Profile preview

Chase Pharmaceuticals

Washington, District of Columbia, United States

Ownership: Private
Development stage: Other

Overview

CPC-201, the company's lead program, is a combination of donepezil (acetylcholinesterase inhibitor) and solifenacin (peripheral cholinergic blocker) designed for improved cognitive benefit and tolerability in Alzheimer's disease. Phase 2 trials demonstrated higher tolerated dosing of donepezil with fewer dose-limiting side effects. At Allergan’s acquisition the program was Phase 3-ready.[2]

Therapeutic areas: Neurology
Modalities: Small moleculeCombination therapy
Industry: Biotech

Beyond the preview

Go deeper on Chase Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chase Pharmaceuticals.

Explore the full profile